1. Search Result
Search Result
Results for "

maytansine

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Inhibitory Antibodies

3

Natural
Products

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13674

    NSC 153858

    Microtubule/Tubulin Cancer
    Maytansine is a highly potent microtubule-targeted compound that induces mitotic arrest and kills tumor cells at subnanomolar concentrations .
    Maytansine
  • HY-156897

    Drug-Linker Conjugates for ADC Cancer
    Val-Cit-amide-Ph-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs) .
    Val-Cit-amide-Ph-Maytansine
  • HY-156896

    Drug-Linker Conjugates for ADC Cancer
    Val-Cit-amide-Cbz-N(Me)-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs) .
    Val-Cit-amide-Cbz-N(Me)-Maytansine
  • HY-130080

    Maytansinoid DM3

    ADC Payload Microtubule/Tubulin Cancer
    DM3 (Maytansinoid DM3), a Maytansine (HY-13674) analog bearing disulfide or thiol groups, and is a tubulin inhibitor. DM3 a cytotoxic moiety of antibody-drug conjugates (ADCs) .
    DM3
  • HY-100504

    Microtubule/Tubulin ADC Payload Cancer
    S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a Kd of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects .
    S-methyl DM1
  • HY-P99492

    SB-408075; huC242-DM1

    Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin Cancer
    Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
    Cantuzumab mertansine
  • HY-19474

    Ansamitocin P-0

    Microtubule/Tubulin ADC Payload Apoptosis Cancer
    Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research .
    Maytansinol
  • HY-171125

    Drug-Linker Conjugates for ADC Cancer
    Maytansine derivative M24 is an ADC Drug-Linker Conjugates for ADC that can be used to synthesize ADC REGN5093-M114 .
    Maytansine derivative M24
  • HY-100503

    ADC Payload Cancer
    Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC .
    Maytansinoid DM4
  • HY-143987

    Others Others
    DM51 impurity 1 is a natural product related to Maytansine (HY-13674) .
    DM51 impurity 1
  • HY-19792
    Mertansine
    Maximum Cited Publications
    22 Publications Verification

    DM1; Maytansinoid DM1

    Microtubule/Tubulin ADC Payload Cancer
    Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
    Mertansine
  • HY-19474R

    Ansamitocin P-0 (Standard)

    Reference Standards Microtubule/Tubulin ADC Payload Apoptosis Cancer
    Maytansinol (Standard) is the analytical standard of Maytansinol. This product is intended for research and analytical applications. Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research[1][2].
    Maytansinol (Standard)
  • HY-130081

    ADC Payload Microtubule/Tubulin Cancer
    DM3-SMe is a maytansine derivative and a tubulin inhibitor, and is a cytotoxic moiety of antibody-drug conjugates (ADCs), which can be linked to antibody through disulfide bond or stable thioether bond. DM3-SMe shows highly cytotoxic activity in vitro with an IC50 of 0.0011 nM .
    DM3-SMe
  • HY-P9921
    Trastuzumab emtansine
    3 Publications Verification

    Ado-Trastuzumab emtansine; PRO132365; T-DM 1

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine
  • HY-P9921A
    Trastuzumab emtansine (solution)
    3 Publications Verification

    Ado-Trastuzumab emtansine (solution); PRO132365 (solution); T-DM 1 (solution)

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine), and the drug-linker conjugate for ADC is SMCC-DM1 (HY-101070). Trastuzumab emtansine can be used for the research of advanced breast cancer .
    Trastuzumab emtansine (solution)
  • HY-W074975

    5-Amino-1,3,4-thiadiazole-2-sulfonamide

    Carbonic Anhydrase Cancer
    CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is a selective inhibitor of carbonic anhydrase B (HCA-B) and isoforms I, II, IV, and VII. CL 5343 has a Ki of 7.9 nM for hCA II. CL 5343 acts as a CA9 ligand to achieve targeted delivery of maytansine to the cell membrane of SKRC52 ??renal cancer cells. CL 5343 is useful in the development of therapeutics for diseases associated with CA overactivity, such as glaucoma, epilepsy, and cancer .
    CL 5343
  • HY-136261

    Drug-Linker Conjugates for ADC Cancer
    DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DM1-PEG4-DBCO
  • HY-136260

    Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-Ahx-DM1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: